71
edits
Changes
→Primary Author(s)*
==Primary Author(s)*==
==Primary Author(s)*==
Parastou Tizro, MD, Celeste C. Eno, PhD, Sumire Kitahara, MD
Parastou Tizro, MD, Celeste C. Eno, PhD, Sumire Kitahara, MD
Cedars-Sinai, Los Angeles, CA
==WHO Classification of Disease==
==WHO Classification of Disease==
{| class="wikitable"
{| class="wikitable"
**5 x 10<sup>9</sup>/L cells of T PLL phenotype in peripheral blood or bone marrow
**5 x 10<sup>9</sup>/L cells of T PLL phenotype in peripheral blood or bone marrow
**T cell clonality by molecular or flow cytometry methods
**T cell clonality by molecular or flow cytometry methods
**Abnormalities of 14q32 or Xq28 or expression of TCL1A/B or MTC**
**Abnormalities of 14q32 or Xq28 or expression of TCL1A/B or MTC**
*'''Minor criteria:'''
*'''Minor criteria:'''
**Abnormalities involving chromosome 11
**Abnormalities involving chromosome 11
The genetic diagnostic process involves detecting clonal rearrangements of the TR gene and rearrangements of the ''TCL1'' gene at the ''TRB'' or ''TRG'' loci.
The genetic diagnostic process involves detecting clonal rearrangements of the TR gene and rearrangements of the ''TCL1'' gene at the ''TRB'' or ''TRG'' loci.
* Cytogenetics (FISH, CpG-stimulated Karyotype, SNP microarray)
*Cytogenetics (FISH, CpG-stimulated Karyotype, SNP microarray)
* PCR for TRB/TRG
*PCR for TRB/TRG
* Next-Generation Sequencing (NGS)
*Next-Generation Sequencing (NGS)
==Familial Forms==
==Familial Forms==